ERBB2 and neoplasm: Of the three patients (43%) with SD after two cycles, one patient whose tumour was co-amplified for c-MYC and HER2 went on to achieve disease control for 32 weeks after nine cycles of treatment with a partial metabolic response in the primary tumour on serial PET–CT scans (Figure S1).